Nuvalent (NUVL) Net Cash Flow (2020 - 2026)
Nuvalent's (NUVL) quarterly Net Cash Flow came in at -$102.0 million in Q1 2026, down 310.41% YoY from $48.5 million in Q1 2025, and down 169.87% on a QoQ basis from $146.0 million in Q4 2025.
Nuvalent (NUVL) Net Cash Flow (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Net Cash Flow data on file, last reported at -$102.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 310.41% year-over-year to -$102.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.9 million (up 74.27% YoY) and the FY2025 annual result came in at $116.1 million, up 161.18% from the prior year.
- Net Cash Flow fell to -$102.0 million in Q1 2026, from $146.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $291.5 million in Q3 2024 to a low of -$236.9 million in Q1 2024.
- A 5-year average of $5.4 million and a median of -$1.3 million in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 4312.56% in 2023, down 12006.23% in 2023.
- Tracing NUVL's Net Cash Flow over 5 years: stood at $165.5 million in 2022, then soared by 49.22% to $247.0 million in 2023, then slumped by 190.52% to -$223.6 million in 2024, then jumped by 165.31% to $146.0 million in 2025, then tumbled by 169.87% to -$102.0 million in 2026.
- The last three Net Cash Flow figures came in at -$102.0 million (Q1 2026), $146.0 million (Q4 2025), and -$11.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | -102.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.01 Mn |
| Mar 31, 2026 | -102.01 Mn |
| Dec 31, 2025 | 145.99 Mn |
| Dec 31, 2025 | 145.99 Mn |
| Sep 30, 2025 | -11.72 Mn |
| Sep 30, 2025 | -11.72 Mn |
| Jun 30, 2025 | 6.64 Mn |
| Jun 30, 2025 | 6.64 Mn |
| Mar 31, 2025 | -24.86 Mn |
| Mar 31, 2025 | -24.86 Mn |
| Dec 31, 2024 | -223.55 Mn |
| Dec 31, 2024 | -223.55 Mn |
| Sep 30, 2024 | 291.54 Mn |
| Sep 30, 2024 | 291.54 Mn |
| Jun 30, 2024 | -20.82 Mn |
| Jun 30, 2024 | -20.82 Mn |
| Mar 31, 2024 | -236.87 Mn |
| Mar 31, 2024 | -236.87 Mn |
| Dec 31, 2023 | 246.95 Mn |
| Dec 31, 2023 | 246.95 Mn |